- Home
- PPBT vs CANF Comparison
PPBT vs CANF Comparison
Compare PPBT & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PPBT | CANF |
|---|---|---|
| Founded | 2010 | 1994 |
| Country | Israel | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4M | 4.7M |
| IPO Year | 2014 | 2011 |
Fundamental Metrics
Financial Performance| Metric | PPBT | CANF |
|---|---|---|
| Price | $4.32 | $3.35 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $30.00 | ★ $50.00 |
| AVG Volume (30 Days) | 10.7K | ★ 908.0K |
| Earning Date | 05-20-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $2,715,455.50 |
| Revenue Next Year | N/A | $101.06 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.41 | $0.17 |
| 52 Week High | $5.18 | $10.40 |
Technical Indicators
Market Signals| Indicator | PPBT | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 52.48 | 57.13 |
| Support Level | $3.70 | $2.91 |
| Resistance Level | $4.39 | $4.74 |
| Average True Range (ATR) | 0.34 | 0.27 |
| MACD | -0.09 | 0.07 |
| Stochastic Oscillator | 40.35 | 42.40 |
Price Performance
Historical ComparisonAbout PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.